Unterberg Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Unterberg Capital’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-100,000	Closed	-$370K	–	33
2017 Q4	$370K	Buy	+100,000	New	+$409K	0.45%	29

Unterberg Capital's CASC Position: Q1 2018 in Review

Unterberg Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 100,000 shares — an estimated $370K sold.

Unterberg Capital first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $370K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Unterberg Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Unterberg Capital sold 100,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $370K.
Unterberg Capital first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Unterberg Capital's Cascadian Therapeutics, Inc. position peaked at $370K in Q4 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Unterberg Capital's 13F filing for Q1 2018, filed 1 May 2018.